Loading…
Loading…
EQUITY / NASDAQ · XNCM
Pasithea Therapeutics Corp.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.476 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.476 USD · Volume 59,962
681 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -5,713,282 USD | -3,810,899 USD | — |
| Net income | -5,273,852 USD | -3,716,157 USD | — |
| Cash and cash equivalents | 45,663,782 USD | 7,217,052 USD | +532.72% |
| Total liabilities | 1,870,258 USD | — | — |
| Total equity | 49,839,687 USD | 15,178,445 USD | +228.36% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 45,663,782 USD | — | — | 55,158,939 USD | 55,158,939 USD | 4,122,953 USD | — | 7,217,052 USD |
| Net incomeIncome statement | -5,273,852 USD | -8,143,334 USD | -2,869,482 USD | — | -20,427,683 USD | -3,037,420 USD | -10,316,815 USD | -3,716,157 USD |
| Operating profitIncome statement | -5,713,282 USD | -10,589,926 USD | — | — | -20,857,295 USD | -3,110,055 USD | -10,601,133 USD | -3,810,899 USD |
| Total assetsBalance sheet | 51,709,945 USD | — | — | 60,240,070 USD | 60,240,070 USD | 13,630,664 USD | — | — |
| Total equityBalance sheet | 49,839,687 USD | — | 54,804,914 USD | 55,219,238 USD | 55,219,238 USD | 12,206,682 USD | — | 15,178,445 USD |
| Total liabilitiesBalance sheet | 1,870,258 USD | — | — | 5,020,832 USD | 5,020,832 USD | 1,423,982 USD | — | — |
| Financing cash flowCash flow statement | — | 9,226 USD | — | — | 63,518,800 USD | — | 7,097,190 USD | — |
| Operating cash flowCash flow statement | — | -9,494,736 USD | — | — | -15,211,490 USD | — | -9,814,668 USD | — |
| Investing cash flowCash flow statement | — | — | — | — | 11,000 USD | — | — | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/30/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.